BidaskClub lowered shares of GTX (NASDAQ:GTXI) from a strong-buy rating to a buy rating in a research report released on Wednesday, March 21st.
Several other analysts also recently issued reports on GTXI. Robert W. Baird started coverage on GTX in a report on Tuesday, November 21st. They set an outperform rating and a $17.00 price objective on the stock. Zacks Investment Research cut GTX from a hold rating to a sell rating in a research note on Wednesday, January 10th. ValuEngine raised GTX from a sell rating to a hold rating in a research note on Wednesday, February 7th. Finally, Stifel Nicolaus lifted their target price on GTX from $16.00 to $45.00 and gave the company a buy rating in a research note on Monday, March 5th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of Buy and an average price target of $37.50.
NASDAQ GTXI traded down $0.52 on Wednesday, hitting $18.02. 94,292 shares of the company were exchanged, compared to its average volume of 105,336. GTX has a twelve month low of $2.73 and a twelve month high of $23.40.
GTX (NASDAQ:GTXI) last posted its quarterly earnings data on Monday, March 12th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.05. sell-side analysts expect that GTX will post -1.78 earnings per share for the current year.
A number of large investors have recently added to or reduced their stakes in the business. Abingworth LLP purchased a new position in GTX during the 3rd quarter valued at about $2,781,000. Caxton Corp bought a new stake in shares of GTX in the 3rd quarter valued at approximately $531,000. Millennium Management LLC bought a new stake in shares of GTX in the 4th quarter valued at approximately $749,000. Finally, EAM Investors LLC bought a new stake in shares of GTX in the 4th quarter valued at approximately $551,000. 12.71% of the stock is currently owned by institutional investors.
WARNING: This article was first posted by Macon Daily and is owned by of Macon Daily. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://macondaily.com/2018/04/12/gtx-gtxi-rating-lowered-to-buy-at-bidaskclub-updated-updated-updated.html.
GTX Company Profile
GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other medical conditions. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, stress urinary incontinence (SUI), and Duchenne muscular dystrophy (DMD); and selective androgen receptor degraders (SARDs) to treat progressive castration-resistant prostate cancer (CRPC).
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.